The effectiveness of spironolactone in group 1 pulmonary hypertension patients
Phase 2
Recruiting
- Conditions
- Group 1 pulmonary hypertension.Other specified pulmonary heart diseases
- Registration Number
- IRCT20171120037376N1
- Lead Sponsor
- Vice Chancellor for Research, Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Patients with group 1 pulmonary hypertension; aged between 12 and 76 years.
Exclusion criteria: Eisenmenger's syndrome; congenital diseases; scleroderma, thalassemia, systemic disease, cirrhosis, cor pulmonale, renal failure; frequent readmission and receiving inotropic therapy; left systolic dysfunction; mental disabilities; pulmonary disease of asthma; and unwillingness to follow up.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Systolic and diastolic function of the right ventricle. Timepoint: Before and four months after treatment. Method of measurement: Echo.;Clinical signs (blood pressure, heart rate, and oxygen saturation). Timepoint: Before and four months after treatment. Method of measurement: 6MWD test.
- Secondary Outcome Measures
Name Time Method Serum NT-ProBNP levels. Timepoint: Before and four months after treatment. Method of measurement: ELISA.